Pages that link to "Q43657283"
Jump to navigation
Jump to search
The following pages link to A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder (Q43657283):
Displaying 50 items.
- Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents (Q22241419) (← links)
- Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults (Q22241427) (← links)
- Attention-Deficit Hyperactivity Disorder in Girls (Q22241431) (← links)
- Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (Q22242745) (← links)
- Cognitive enhancers for the treatment of ADHD (Q22251235) (← links)
- The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex (Q22252343) (← links)
- Psychostimulants as Cognitive Enhancers: The Prefrontal Cortex, Catecholamines, and Attention-Deficit/Hyperactivity Disorder (Q22252504) (← links)
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management (Q22252568) (← links)
- Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents (Q24200716) (← links)
- Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders (Q24235048) (← links)
- Heterozygous alpha 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists (Q24535863) (← links)
- The neurobiological basis of ADHD (Q24604400) (← links)
- Contemporary assessment and pharmacotherapy of Tourette syndrome (Q24607941) (← links)
- Neuromodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapses (Q24619549) (← links)
- The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder (Q24629736) (← links)
- Advances in the treatment of fragile X syndrome (Q24632814) (← links)
- Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths (Q24642024) (← links)
- Pharmacotherapy of aggression in children and adolescents: efficacy and effect size (Q24648097) (← links)
- Tourette syndrome and obsessive-compulsive disorder (Q24657240) (← links)
- Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals (Q24682060) (← links)
- Adrenergic pharmacology and cognition: focus on the prefrontal cortex (Q24684217) (← links)
- Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder (Q24810310) (← links)
- Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence (Q26999258) (← links)
- Targeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive Disorders (Q28076907) (← links)
- Tourette syndrome and other tic disorders (Q28235639) (← links)
- Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents (Q28265059) (← links)
- Do adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder? (Q28274915) (← links)
- Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents (Q28282770) (← links)
- A computational psychiatry approach identifies how alpha-2A noradrenergic agonist Guanfacine affects feature-based reinforcement learning in the macaque (Q28468318) (← links)
- Loss of glutamatergic pyramidal neurons in frontal and temporal cortex resulting from attenuation of FGFR1 signaling is associated with spontaneous hyperactivity in mice (Q28585560) (← links)
- Psychopharmacology of Tic Disorders (Q28972388) (← links)
- European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment (Q28972478) (← links)
- Tourette Syndrome in Children: An Updated Review (Q29012887) (← links)
- Sex differences in guanfacine effects on drug craving and stress arousal in cocaine-dependent individuals (Q30576218) (← links)
- Attention-deficit/hyperactivity disorder in children and adolescents (Q30890584) (← links)
- The role of stress in addiction relapse (Q31132188) (← links)
- Syncope in children with Tourette's syndrome treated with guanfacine (Q33153196) (← links)
- Guanfacine overdose resulting in initial hypertension and subsequent delayed, persistent orthostatic hypotension (Q33158355) (← links)
- Behavior therapy for tics in children: acute and long-term effects on psychiatric and psychosocial functioning (Q33555402) (← links)
- The role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals (Q33598487) (← links)
- Cognitive enhancement as a pharmacotherapy target for stimulant addiction (Q33599983) (← links)
- Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity (Q33714538) (← links)
- Lobeline Effects on Cognitive Performance in Adult ADHD. (Q33774323) (← links)
- Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder (Q33782856) (← links)
- Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder (Q33819957) (← links)
- Clinical Characteristics of Children and Adolescents with a Primary Tic Disorder (Q33836242) (← links)
- Levetiracetam as an alternative therapy for Tourette syndrome (Q33966358) (← links)
- Neurobiological substrates of Tourette's disorder (Q34135110) (← links)
- Pharmacological management of tics in patients with TS. (Q34211454) (← links)
- Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. (Q34259426) (← links)